TICKERNERD
Menu
CGONCGONHealthcare · Biotechnology

CGON Stock Forecast: CG Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$80
+2.83% on the day

The 15 Wall Street analysts covering CG Oncology, Inc. hold a median 12-month price target of $90 — +12.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.1B
Ticker Nerd rank
18 / 100
Median analyst target
$90
Analysts covering
15
Total return, dividends reinvested
1W
+6.4%
1M
+11.3%
YTD
+92.2%
1Y
+207.2%
From 52W high
−1.1%
From 52W low
+214.0%
$25
$81
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CG Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Growth
60
Revisions
34
Accruals
30
Value
26
Issuance
26
Volatility
25
Size
19
Quality
9

Momentum (96): The shares have been drifting up relative to others.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120Oct 25Jan 26Apr 26Jul 26CGONHigh $108Median $90Low $79

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $79Median $90High $108

The green dot is the last close — the median target sits +12.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Piper SandlerMaintainsOverweight$82 → $85
7 Aug 2026RBC CapitalMaintainsOutperform$81 → $79
7 Aug 2026Truist SecuritiesMaintainsBuy$82 → $85
19 May 2026Wolfe ResearchInitiatesPeer Perform—
19 May 2026Wolfe ResearchInitiatesPeer Perform—
18 May 2026HC Wainwright & Co.ReiteratesBuy$100
18 May 2026HC Wainwright & Co.ReiteratesBuy—
14 May 2026Truist SecuritiesReiteratesBuy$77 → $82
14 May 2026Truist SecuritiesReiteratesBuy—
11 May 2026JP MorganMaintainsOverweight—
11 May 2026RBC CapitalMaintainsOutperform—
11 May 2026Truist SecuritiesReiteratesBuy—
11 May 2026WedbushMaintainsOutperform—
27 Apr 2026RBC CapitalMaintainsOutperform—
17 Apr 2026JP MorganMaintainsOverweight—
7 Apr 2026HC Wainwright & Co.MaintainsBuy—
27 Feb 2026HC Wainwright & Co.MaintainsBuy—
10 Feb 2026Truist SecuritiesMaintainsBuy—
21 Jan 2026RBC CapitalMaintainsOutperform—
16 Jan 2026Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CGON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
8
Fundamentals

CG Oncology, Inc. (CGON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−38.4×

Cheaper than 98% of US stocks

Price / sales
1135.9×

Cheaper than 1% of US stocks

Price / book
6.8×

Cheaper than 16% of US stocks

EV / EBITDA
−24.3×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
6.8%

Higher than 44% of US stocks

Earnings growth (YoY)
1982.7%

Higher than 99% of US stocks

Gross margin
−239.2%

Higher than 1% of US stocks

Operating margin
−7467.7%

Higher than 2% of US stocks

Net margin
−15.0%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−26.4%

Higher than 28% of US stocks

Return on assets
−17.7%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CGON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGONCG Oncology, Inc.$7.1B
18
ORKAOruka Therapeutics, Inc.$7.1B
41
SRRKScholar Rock Holding Corp.$6.9B
32
CAICaris Life Sciences, Inc.$7.4B
31
RYTMRhythm Pharmaceuticals, Inc.$7.6B
88
COGTCogent Biosciences, Inc.$6.3B
35
MIRMMirum Pharmaceuticals, Inc.$6.3B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CG Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGON news & analysis

CG Oncology: Circling Back After Huge Rally

Seeking Alpha · 14 Aug 2026positive

CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, reporting strong efficacy and best-in-class safety versus competitors, including a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C with no Grade 3+ adverse events. The rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.

Why it matters — CGON watchers would care because the cret efficacy and safety data, along with the upcoming BLA completion and trial readouts, mark key regulatory and clinical milestones for the company's lead program.

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

CG Oncology, Inc. reported a quarterly loss of $0.9 per share for the quarter, which was wider than the Zacks Consensus Estimate of a $0.7 loss and compared with a loss of $0.54 per share a year earlier. The company missed revenue estimates.

Why it matters — CGON watchers would care because the company's quarterly results came in below analyst expectations on both earnings and revenue.

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 6 Aug 2026neutral

CG Oncology, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided accompanying business updates in a press release issued August 6, 2026.

Why it matters — CGON watchers would look to the quarterly financial results and business updates for a view into the company's recent performance and commercial progress.

CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology

GlobeNewsWire · 27 July 2026positive

CG Oncology announced that the results of its pivotal Phase 3 BOND-003 Cohort C study have been published in The Lancet Oncology, showing durable responses, bladder preservation, a low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Why it matters — Publication in a prestigious peer-reviewed journal strengthens the credibility of CG Oncology's clinical data for a key pipeline asset.

FAQ

Frequently asked questions about CGON stock

What is the CGON stock price forecast for 2026-2027?

The 15 Wall Street analysts covering CG Oncology, Inc. have a median 12-month price target of $90, with estimates ranging from $79 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGON stock a buy right now?

Of the 15 analysts covering CG Oncology, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CG Oncology, Inc. 18 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGON?

As at 22 Aug 2026, CG Oncology, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will CGON stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +12.8% from the last close, and Ticker Nerd's factor model ranks CG Oncology, Inc. 18 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGON stock forecast for 2030?

No analyst covering CG Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $108 over the next 12 months.

How has CGON stock performed over the past year?

CG Oncology, Inc. returned +207.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CG Oncology, Inc. do?

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC).

What is the latest news on CGON?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "CG Oncology: Circling Back After Huge Rally". CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, reporting strong efficacy and best-in-class safety versus competitors, including a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C with no Grade 3+ adverse events. The rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.

Company

About CG Oncology, Inc.

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing immunotherapies for patients with bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Its lead investigational candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy currently advancing through two Phase 3 clinical trials—BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC—as well as the Phase 2 CORE-008 study combining it with a checkpoint inhibitor for high-risk BCG-unresponsive disease. The company targets urologic cancers, addressing significant unmet needs in BCG-unresponsive and intermediate-risk settings where durable, bladder-preserving options are limited. Headquartered in Irvine, California, CG Oncology engages in clinical development, regulatory interactions including a rolling Biologics License Application submission and Fast Track designation, and supports research through programs like fellowships at urologic conferences. This positions CG Oncology as a key player in oncology biotechnology, emphasizing innovative intravesical therapies to improve patient outcomes in bladder cancer treatment.

CEO Mr. Arthur Kuan · 142 employees · United States · https://cgoncology.com